Skip to content

Advertisement

Open Access

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

  • Yiwen Li1, 6Email author,
  • Carmine Carpenito1,
  • George Wang1,
  • David Surguladze2,
  • Amelie Forest1,
  • Maria Malabunga1,
  • Mary Murphy1,
  • Yiwei Zhang3,
  • Andreas Sonyi1,
  • Darin Chin1,
  • Douglas Burtrum3,
  • Ivan Inigo2,
  • Anthony Pennello2,
  • Leyi Shen1,
  • Laurent Malherbe4,
  • Xinlei Chen5,
  • Gerald Hall1,
  • Jaafar N. Haidar1,
  • Dale L. Ludwig3,
  • Ruslan D. Novosiadly1 and
  • Michael Kalos1, 6, 7Email author
Journal for ImmunoTherapy of Cancer20186:45

https://doi.org/10.1186/s40425-018-0354-6

Received: 11 May 2018

Accepted: 14 May 2018

Published: 4 June 2018

The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:31

Correction

Unfortunately, after publication of this article [1], it was noticed that corrections to the legends of Figs. 1 and 2 were not correctly incorporated. The correct legends can be seen below.

The original article has also been updated.

Figure 1 Binding and blocking properties of LY3300054. Panels a–c: 96-well plates were coated with recombinant human (a), cynomolgus (b), or murine (c) PD-L1-Fc fusion protein (100 ng/well each). Bound LY3300054 was detected using HRP-conjugated anti-human Fab antibody and addition of chromogenic substrate (OD at 450 nm). 96-well plates were coated with 100 ng/well of recombinant PD-1 (d) or B7-1 protein (e), then incubated with a mixture of biotin-conjugated PD-L1 and either LY3300054 or human IgG1 antibodies. Plate bound PD-L1 was detected using HRP-conjugated streptavidin and addition of chromogenic substrate (OD at 450 nm). In all experiments, each data point is the average of two replicates. Data (a-e) are representative of multiple independent experiments

Figure 2 Identification of LY3300054 epitope residues in human PD-L1. Panel a: CLUSTALW multiple sequence alignment of domain 1 of human (hu), canine (ca), and murine (mu) PD-L1 and hu-PD-L2 to identify the LY3300054 species specificity anchors on hu-PD-L1. Underlined is the human PD-1 6 Å binding site on hu-PD-L1 (according to PDB: 4ZQK (26602187)). An alignment position is marked with (*) if both mu-PD-L1 and ca-PD-L1 substitutions differ from the hu-PD-L1 sequence. An alignment position is marked with (:) if either the mu-PD-L1 or ca-PD-L1 substitution differs from the hu-PD-L1 sequence. Panel b: Position N63 on human PD-L1 is a specificity anchor for LY3300054. Canine-to-human mutation K63 N (▲) rescues the ELISA binding of LY3300054 to canine PD-L1. Like wild type ca-PD-L1-Fc (), canine-to-human mutant N69H () does not bind LY3300054

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Lilly Research Laboratories, Department of Cancer Immunobiology, New York, USA
(2)
Lilly Research Laboratories, Department of Preclinical Pharmacology, New York, USA
(3)
Lilly Research Laboratories, Department of Biologics Technology, New York, USA
(4)
Lilly Research Laboratories, Department of Non-Clinical Safety, Indianapolis, USA
(5)
Lilly Research Laboratories, Department of Quantitative Biology, New York, USA
(6)
Eli Lilly and Company, New York, USA
(7)
Janssen Pharmaceutical Companies of Johnson and Johnson, Springhouse, USA

Reference

  1. Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, et al. Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J Immunother Cancer. 2018;6:31. https://doi.org/10.1186/s40425-018-0329-7.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement